Marijn C Visschedijk
Overview
Explore the profile of Marijn C Visschedijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holstein H, Bouwknegt D, Visschedijk M, Bulthuis M, Reinders-Luinge M, Schoots M, et al.
Free Radic Biol Med
. 2025 Mar;
PMID: 40089080
Background: Inflammatory bowel disease (IBD) often presents during the fertile age and may affect pregnancy outcomes. Both IBD and selected pregnancy complications involve oxidative stress. Soluble FMS-like tyrosine kinase-1 (sFlt-1)...
2.
Stevens C, Adriaans G, Spooren C, Peters V, Pierik M, Weersma R, et al.
Clin Nutr
. 2025 Mar;
47:212-226.
PMID: 40048994
Background & Aims: Diet is an important environmental factor in inflammatory bowel disease (IBD) onset and disease course, but analyses are hindered by its complexity. We aim to explore the...
3.
Bredero Q, Fleer J, Smink A, Kuiken G, Potjewijd J, Laroy M, et al.
J Psychosom Res
. 2024 Oct;
187():111949.
PMID: 39418854
Objectives: Fatigue is prevalent in patients with inflammatory bowel disease (IBD) in remission. Previously, we showed that fatigued IBD patients experienced a significant decrease in fatigue after receiving mindfulness-based cognitive...
4.
Prins F, Hidding I, Klaassen M, Collij V, Schultheiss J, Uniken Venema W, et al.
Gut Microbes
. 2024 Aug;
16(1):2391505.
PMID: 39167702
Emerging evidence suggests the gut microbiome's potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response...
5.
Bourgonje A, Visschedijk M, Festen E, Weersma R, Dijkstra G
Lancet Gastroenterol Hepatol
. 2024 Jun;
9(7):590-591.
PMID: 38870963
No abstract available.
6.
Schaafsma I, Hoogenboom F, Dijkstra G, Prins J, Visschedijk M
AJOG Glob Rep
. 2024 Apr;
4(2):100333.
PMID: 38655569
Background: Pregnant women with active perianal Crohn's disease indicate a cesarean delivery according to the current European Crohn's and Colitis Organisation guidelines. This advice is based on the assumption that...
7.
Bak M, Hammoudi N, Allez M, Silverberg M, Schellekens I, Erler N, et al.
Gastrointest Endosc
. 2024 Mar;
100(4):703-709.e4.
PMID: 38462057
Background And Aims: The modified Rutgeerts score (mRS) is widely used for the assessment of endoscopic postoperative recurrence (ePOR) in Crohn's disease (CD) after ileocolic resection to guide therapeutic decisions....
8.
Hu S, Bourgonje A, Gacesa R, Jansen B, Bjork J, Bangma A, et al.
Nat Commun
. 2024 Feb;
15(1):1470.
PMID: 38368394
Disrupted host-microbe interactions at the mucosal level are key to the pathophysiology of IBD. This study aimed to comprehensively examine crosstalk between mucosal gene expression and microbiota in patients with...
9.
Otten A, Dijkstra G, Visschedijk M, Bourgonje A
Inflamm Bowel Dis
. 2023 Jul;
30(2):318-319.
PMID: 37523671
No abstract available.
10.
Otten A, van der Meulen H, Steenhuis M, Loeff F, Touw D, Kosterink J, et al.
Inflamm Bowel Dis
. 2023 Jun;
30(3):325-335.
PMID: 37265165
Background: Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed to validate a...